FDA has approved Empliciti (elotuzumab) injection for intravenous use in combination with pomalidomide and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least two prior therapies, including lenalidomide and a proteasome inhibitor.
Kate Choi grew up hearing conversations about skin cancer. Her grandparents had it, as did her cousins.
